Prior P, Pope D J
Department of Social Medicine, University of Birmingham, UK.
Br J Cancer. 1988 Oct;58(4):512-7. doi: 10.1038/bjc.1988.253.
A consecutive series of 2,999 patients, diagnosed with Hodgkin's disease (HD) between 1950 and 1979, was assembled from the records of the Birmingham and West Midlands Cancer Registry and followed to the end of 1984. Cohort analyses of subsequent primary cancers among 1,976 patients, surviving one or more years (mean follow-up 6.7 person-years), were carried out in relation to overall treatment by radiotherapy (RT), chemotherapy (CT) or both modalities (CT + RT). Over all sites a 50% increase in risk, relative to the West Midlands population, was found [observed (O) = 65; relative risk (RR) = 1.5; P less than 0.01]. Among patients treated by CT (with or without RT) a significant increase in acute and non-lymphocytic leukaemias was found (O = 6; RR = 30.0; P less than 0.001). The excess risk was of the order of 1 per 1000 patient-years and the cumulative risk was 1.2%. Among solid tumours increased risks, which might be attributable to RT, occurred in the lung (O = 15; RR = 1.6; P less than 0.05), breast (O = 9; RR = 2.2; P less than 0.05) and bone (O = 2; RR = 20.0; P less than 0.01). The excess of skin cancers (O = 13; RR = 2.9; P less than 0.01) occurred mainly within 10 years of treatment with CT. The follow-up period is still insufficient to determine the long-term effect on the incidence of solid tumours with long latent periods from multiple-agent CT which became more frequently used in the early 1970s. A sub-set of these data was analysed over all treatments and the results were contributed to an international study co-ordinated by the International Agency for Research on Cancer, Lyon.
从伯明翰和西米德兰兹癌症登记处的记录中收集了1950年至1979年间连续确诊的2999例霍奇金病(HD)患者,并随访至1984年底。对1976例存活一年或更长时间(平均随访6.7人年)的患者随后发生的原发性癌症进行队列分析,分析与放疗(RT)、化疗(CT)或两种方式(CT + RT)的总体治疗相关情况。在所有部位,相对于西米德兰兹人群,发现风险增加了50%[观察值(O)= 65;相对风险(RR)= 1.5;P < 0.01]。在接受CT治疗(无论是否联合RT)的患者中,急性非淋巴细胞白血病显著增加(O = 6;RR = 30.0;P < 0.001)。额外风险约为每1000患者年1例,累积风险为1.2%。在实体瘤中,可能归因于RT的风险增加发生在肺癌(O = 15;RR = 1.6;P < 0.05)、乳腺癌(O = 9;RR = 2.2;P < 0.05)和骨癌(O = 2;RR = 20.0;P < 0.01)。皮肤癌的增加(O = 13;RR = 2.9;P < 0.01)主要发生在CT治疗后的10年内。随访期仍不足以确定20世纪70年代初更频繁使用的多药联合CT对潜伏期长的实体瘤发病率的长期影响。对这些数据的一个子集进行了所有治疗方法的分析,结果提交给了由里昂国际癌症研究机构协调的一项国际研究。